2,2′:6′,2″:6″,2‴-Quaterpyridine has been prepared in 40–45% yield by the nickel(0) coupling of a 6-halogeno-2,2′-bipyridine. The reaction initially yields a nickel(II) complex of 2,2′:6′, 2′:6″,2‴-quaterpyridine which may be demetallated by treatment with NaCN. The crystal and molecular structures of 2,2′:6′,2″:6″,2‴-quaterpyridine [monoclinic, a= 6.348(1), b= 8.179(2), c= 14.894(3)Å, β= 100.15(1)°, space group P21/n, Z= 2] and bis(acetonitrile)-(2,2′:6′,2″:6″,2‴-quaterpyridine)nickel(II) hexafluorophosphate-acetonitrile (1/1)[monoclinic, a= 22.348(9), b= 11.504(5), c= 15.636(6)Å, β= 128.41 (2)°, space group C2/c, Z= 4] have been determined. The free ligand is essentially planar with transoid arrangements of the pyridyl rings as observed in 2,2′-bipyridine. The nickel complex is approximately octahedral with the 2,2′:6′,2″:6″,2‴-quaterpyridine occupying the equatorial sites; the Ni–N distances to the terminal pyridine rings are longer than those to the inner rings.
No takes yet. Share an insight, caveat, or question.
Constable et al. (1990) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: